Table 1.

Patient characteristics in 6 patient cohorts

	Cohort 1 (N = 229)	Cohort 2 (N = 168)	Cohort 3 (N = 506)	Cohort 4 (N = 125)	Cohort 5 (N = 80)	Cohort 6 (N = 195)
Gender
Male	123 (53.7%)	90 (53.6%)	279 (55.1%)	63 (50.4%)	44 (55.0%)	103 (52.8%)
Female	106 (46.3%)	78 (46.4%)	227 (44.9%)	62 (49.6%)	36 (45.0%)	92 (47.2%)
Age
Median (range)	67 (26–92)	67 (22–97)	68 (22–97)	68 (23–87)	60.5 (25–89)	69 (35–90)
Location
Right colon	102 (44.5%)	57 (33.9%)	206 (40.7%)	50 (40.0%)	NA	67 (34.4%)
Left colon	95 (41.5%)	72 (42.9%)	300 (59.3%)	65 (52.0%)	NA	65 (33.3%)
Rectum	30 (13.1%)	0 (0.0%)	0 (0.0%)	10 (8.0%)	NA	62 (31.8%)
Unknown	2 (0.9%)	39 (23.2%)	0 (0.0%)	0 (0.0%)	NA	1 (0.5%)
Stage
I	44 (19.2%)	4 (2.4%)	37 (7.3%)	28 (22.4%)	0 (0.0%)	43 (22.1%)
II	94 (41.0%)	88 (52.4%)	264 (52.2%)	48 (38.4%)	0 (0.0%)	72 (36.9%)
III	91 (39.7%)	76 (45.2%)	205 (40.5%)	49 (39.2%)	0 (0.0%)	49 (25.1%)
IV	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	80 (100.0%)	29 (14.9%)
Unknown	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.0%)
Adjuvant chemotherapy
Yes	87 (38.0%)	23 (13.7%)	203 (40.1%)	NA	NA	NA
No	142 (62.0%)	15 (8.9%)	301 (59.5%)	NA	NA	NA
Unknown	0 (0.0%)	130 (77.4%)	2 (0.4%)	NA	NA	NA
KRAS status
Wild type	NA	NA	297 (58.7%)	NA	43 (53.8%)	115 (59.0%)
Mutant	NA	NA	188 (37.2%)	NA	27 (33.8%)	80 (41.0%)1
Unknown	NA	NA	21 (4.2%)	NA	10 (12.5%)	0 (0.0%)
MSI status
pMMR	NA	NA	388 (76.7%)	87 (69.6%)	NA	172 (88.2%)
dMMR	NA	NA	73 (14.4%)	28 (22.4%)	NA	23 (11.8%)
Unknown	NA	NA	45 (8.9%)	10 (8.0%)	NA	0 (0.0%)
YAP1 signature
IYCC	163 (71.2%)	102 (60.7%)	366 (72.3%)	92 (73.6%)	57 (71.3%)	166 (85.1%)
AYCC	66 (28.8%)	66 (39.3%)	140 (27.7%)	33 (26.4%)	23 (28.8%)	29 (14.9%)

^#Abbreviations: MSI, microsatellite instability; pMMR, proficient mismatch repair; dMMR, deficient mismatch repair; IYCC, inactivated YAP1 colorectal cancer; AYCC, activated YAP1 colorectal cancer; NA, not available